Computational Chemistry Shared Resource (CCSR)

Selected Publications

1. Chen Shen, Anmada Nayak, Leif R. Neitzel, Amber A. Adams, Maya Silver-isenstadt, Leah M. Sawyer, Hassina Benchabane, Huilan Wang, Nawat Bunnag, Bin Li, Daniel T. Wynn, Fan Yang, Marta Garcia-contreras, Charles H. Williams, Sivanesan Dakshanamurthy, Charles C. Hong, Nagi G. Ayad, Anthony J. Capobianco, Yashi Ahmed, Ethan Lee And David J. Robbins. “The E3 Ubiquitin Ligase Component, Cereblon, Is An Evolutionarily Conserved Regulator Of Wnt Signaling.” Nature Communications 12, 5263 (2021), 12, 1 (September 6, 2021) DOI: https://doi.org/10.1038/s41467-021-25634-z. (new window)
2. Naeem Aisha, Dakshanamurthy Sivanesan, Parasido Erika, Avantaggiati Maria, Tricoli Lucas, Kumar Deepak, Lee Richard, Feldman Adam, Noon Muhammad, Byers Stephen, Rodriguez Olga, Albanese Chris. Predicting new drug indications for prostate cancer: The integration of an in-silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. Prostate 2020 Oct;80(14):1233-1243. doi: 10.1002/pros.24050. https://pubmed.ncbi.nlm.nih.gov/32761925/
3. Ivana Peran, Sivanesan Dakshanamurthy , Matthew McCoy , Michael Pishvaian , Sara Sprague , Eveline Vietsch , Anton Wellstein , Michael Atkins , Louis Weiner , Stephen Yoo , Shahin Assefnia , Stephen Byers. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Gastroenterology 2021 Mar;160(4):1359-1372.e13. https://pubmed.ncbi.nlm.nih.gov/33307028/
4. Issa NT, Stathias V, Schürer S, Dakshanamurthy S. Machine and deep learning approaches for cancer drug repurposing. Semin Cancer Biol. 2020 Jan 3. pii: S1044-579X(19)30409-2. https://www.ncbi.nlm.nih.gov/pubmed/31904426
5. Ullah H, Hou W, Dakshanamurthy S, Tang Q. Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation. Oncotarget. 2019 May 14;10(35):3209-3226. https://www.ncbi.nlm.nih.gov/pubmed/31143369
6. Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S. Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. Oncotarget. 2017 Oct 9;8(54):92926-92942. https://www.ncbi.nlm.nih.gov/pubmed/29190967
7. Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget. 2017 Feb 21;8(8):12576-12595. https://www.ncbi.nlm.nih.gov/pubmed/28157711
8. Issa NT, Peters OJ, Byers SW, Dakshanamurthy S. RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions. Comb Chem High Throughput Screen. 2015;18(8):784-94. https://www.ncbi.nlm.nih.gov/pubmed/26234515
9. Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 2014 Aug;46(8):844-9. https://www.ncbi.nlm.nih.gov/pubmed/24974848